HQHan Qu

Han Qu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Han Qu has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Age-Stratified Disproportionality Analysis of Bruton's tyrosine kinase inhibitors in FAERS and VigiBase

    by Han Qu, Yuqi Jia, Zizhen Liu, Zuan Li, Xin Zhao, Zhenghua Wu, Guorong Fan, Yuefen Lou

    Introduction: Bruton's Tyrosine Kinase inhibitors (BTKis) are increasingly used because of their efficacy; however, safety concerns are emerging. Methods: This study extracted data from FAERS and VigiBase and divided patients into four age groups. The Reporting Odds Ratio (ROR) was used to identify safety signals. Results: Regarding cardiac disorders, zanubrutinib showed a specific cardiac arrest signal in the 0-60-year age group in FAERS, and the Atrial Fibrillation (AF) signal intensity increased with age in VigiBase. Conversely, the AF signals decreased across successive age groups for acalabrutinib in VigiBase and for ibrutinib in both databases. Several cardiac PTs for acalabrutinib met the signal criteria in the 61-70-year group. For skin and subcutaneous tissue disorders, multiple nail-related Adverse Drug Events (ADEs) were observed in all age groups for ibrutinib; acalabrutinib and zanubrutinib exhibited no nail-related signals, whereas other skin-related signals were primarily detected in patients aged >60 years. Regarding bleeding ADEs, thirty types were detected for ibrutinib and four for acalabrutinib; zanubrutinib showed no age-specific bleeding signals. For infections and infestations, among the PTs detected in three or more age groups, aspergillus infection, bronchopulmonary aspergillosis, and onychomycosis were consistently ranked among the top ten signals for ibrutinib based on VigiBase ROR025 across all four age groups, with ROR025 values decreasing with increasing age. Signals for different types of pneumonia were detected in all age groups for the BTKis, except in the 0-60- year age group of zanubrutinib. Moreover, the specific signals warrant further attention. Discussion: This comprehensive analysis of FAERS and VigiBase data highlights agerelated differences in ADE reporting across BTKi therapies. These findings identify age-stratified reporting patterns that may help prioritize further safety investigations. A limitation of this study is the lack of integration of potential biological mechanisms underlying BTKi-related ADEs. Conclusion: This study identified age-stratified reporting patterns for three BTKis in two spontaneous reporting systems. These findings are hypothesis-generating and do not establish differences in clinical risk across age groups or causal relationships.

  • Multi-technology integrated network pharmacology-based study on phytochemicals, active metabolites, and molecular mechanism of Psoraleae Fructus to promote melanogenesis

    by Xuemei Yu, Yuanyuan Wang, Zhenghua Wu, Mengqi Jia, Ying Xu, Han Qu, Xin Zhao, Shuowen Wang, Lili Jing, Yuefen Lou, et al.


  • Open Access

    Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials

    by Li Wang, Yibo Fei, Han Qu, Haiyang Zhang, Yuanyuan Wang, Zhenghua Wu, Guorong Fan

    Objective: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. It has a wide range of clinical applications in various cancers and retinal diseases. The drugs entered the Chinese market by a large margin in 2017, and the user population changed to some extent. This study reevaluated the safety of bevacizumab through an analysis of the World Pharmacovigilance database (Food and Drug Administration Open Vigil 2.1) in conjunction with a comprehensive meta-analysis of RCTs. Methods: Real-world pharmacovigilance data originating from case reports were mined using Open Vigil and coded at the preferred term (PT) level using the Standardized MedDRA Query. Proportional reporting ratios (PRR) and reporting odds ratios (ROR) were used to detect safety signals. Eligible items were screened by searching PubMed, Wanfang, and Web of Science, and data were extracted for systematic review and meta-analysis using RevMan 5.4 software. Results: Analysis of the drug pharmacovigilance database revealed that the most significant PRRs were limb decortication syndrome (PRR = 2926), stomal varices (PRR = 549), anastomotic (PRR = 457) and ureteral fistula (PRR = 406). Most safety signals at the PT level emerged as various types of injuries, toxicities, operational complications, systemic diseases, various reactions at the administration site, hematological and lymphatic disorders, and gastrointestinal disorders. Adverse reactions such as nasal septal perforation (PRR = 47.502), necrotizing fasciitis (PRR = 20.261), and hypertensive encephalopathy (PRR = 18.288) listed as rare in drug specifications should not be ignored with a high signal in the real world. A total of 8 randomized controlled trials (RCTs) were included in the meta-analysis, and the overall risk of adverse reactions following bevacizumab administration was relatively low, indicating a good safety profile (HR = 1.19, 95% CI:0.85 ~ 1.65, p = 0.32). Conclusion: The frequent adverse reactions of bevacizumab occurring in the real world are consistent with the data provided in RCTs and drug specifications. However, adverse reactions such as nasal septum perforation, necrotizing fasciitis, hypertensive encephalopathy and so on, listed as rare in drug specifications, may have a high signal of correlation in the real world, which all requires active monitoring and timely adjustment of bevacizumab posology during its clinical use.


  • Open Access

    Recycling preparative isolation of six bicyclol active metabolites from SD rat urine using macroporous resin, offline 2D LPLC/HPLC, and prep-HPLC combined with pharmacodynamic evaluation of two active metabolites

    by Xucong Huang, Zhenghua Wu, Xijier Qiaolongbatu, Han Qu, Cui Ma, Yujie Xiang, Mengqi Jia, Yanchao Liu, Shuowen Wang, Lili Jing, et al.

    In our previous study, several bicyclol (BIC) metabolites were found to possess higher solubility, security, and efficacy than the parent drug. However, further research can’t be conducted without monomeric metabolites. In the current study, a highly efficient preparative approach for six BIC-active metabolites from Sprague-Dawley (SD) rat urine was developed. First, 1000 mL of urine was purified and concentrated to 50 mL using microporous resin. Second, middle chromatogram isolated (MCI) GEL®CHP20P adsorbent was used to create a low-pressure liquid chromatography (LPLC) column, which was combined with high-performance liquid chromatography (HPLC) to build an offline 2D system to visualize the separation process. Samples were segmented into 25 tubes and merged into three fractions. Then, recycling preparative HPLC was applied to the monomeric preparation to improve the efficiency. The prepared metabolites possessed high purity (greater than98%), and were verified by nuclear magnetic resonance (NMR). Finally, an isoniazid (INH)-induced liver injury zebrafish model was established to evaluate the efficiency of the BIC, M7, and M8 metabolites. The M7 metabolite exhibited a higher efficiency than BIC in histopathology, gene expression, and aminotransferase levels. Consequently, this study provided a strategy that integrating modern analytical techniques to prepare metabolites for discovering high value candidate compounds from biological metabolism.


  • Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real‐World Pharmacovigilance and Randomized Clinical Trials

    by Han Qu, Jiaqi Wu, Cui Ma, Xijier Qiaolongbatu, Xianmin Song, Tingting Feng, Zhenghua Wu, Yuefen Lou, Guorong Fan

    Eltrombopag is clinically approved for use in immune thrombocytopenia (ITP), chronic hepatitis C‐related thrombocytopenia, and aplastic anemia and suitable for children; however, data on its overall safety profile are scarce. This study aimed to explore the clinical features of adverse drug events (ADEs) associated with eltrombopag in different age groups using individual case safety reports (ICSRs) from the World Health Organization database VigiBase and the US Food and Drug Administration Adverse Event Reporting System database from 2008 to 2022 in combination with a meta‐analysis of data from randomized clinical trials in the literature from inception to July 28, 2022. We conducted disproportionality analyses by grouping patients into the following age groups: 0–17 (0–23 months, 2–11 years, and 12–17 years), 18–64, and ≥ 65 years. The ADEs about hepatobiliary disorders, thrombosis, skin and subcutaneous tissue disorders, infections, and so on were observed more differently in each age group. Meta‐analysis results showed differences in the four system organ classes between adults and children with ITP: infections and infestations, general disorders and administration site conditions, skin and subcutaneous tissue disorders, and investigations. The adverse drug reactions in the latest version of instructions were searched in the databases to analyze their postmarketing safety signal strength. We observed signals of elevated alanine aminotransferase, aspartate aminotransferase, and blood bilirubin levels in all age groups. For children, urinary tract infection and back pain showed signals. Due to the inherent limitations of pharmacovigilance studies, more experiments are needed to assess the risks of eltrombopag in different ages.


  • Open Access

    The Therapeutic Mechanism of Schisandrol A and Its Metabolites on Pulmonary Fibrosis Based on Plasma Metabonomics and Network Analysis

    by Xijier Qiaolongbatu, Wenjuan Zhao, Xucong Huang, Feng Qian, Xinyi Yang, Jiaqi Wu, Cui Ma, Han Qu, Li Wang, Guorong Fan, et al.

    Background: Schisandrol A (Sch A) is the main active ingredient of Schisandra chinensis (Turcz.) Baill. Our previous study showed that Sch A has anti-pulmonary fibrosis (PF) activity, but its metabolic-related mechanisms of action are not clear. Methods: Here, we explored the therapeutic mechanisms of Sch A on PF by ultra-high performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) metabolomics approach and network analysis. The metabolites of Sch A in mice (bleomycin + Sch A high-dose group) plasma were identified based on ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS). Results: 32 metabolites were detected reversed to normal level after treating bleomycin (BLM)-induced PF mice with Sch A. The 32 biomarkers were enriched in energy metabolism and several amino acid metabolisms, which was the first report on the therapeutic effects of Sch A on PF through rescuing the disordered energy metabolism. The UPLC-Q-TOF/MS analysis identified 17 possible metabolites (including isomers) of Sch A in mice plasma. Network analysis revealed that Sch A and 17 metabolites were related to 269 genes, and 1109 disease genes were related to PF. The construction of the Sch A/metabolites-target-PF network identified a total of 79 intersection genes and the TGF-β signaling pathway was determined to be the main signaling pathway related to the treatment of PF by Sch A. The integrated approach involving metabolomics and network analysis revealed that the TGF-β 1-ID3-creatine pathway, TGF-β 1-VIM-carnosine pathway were two of the possible pathways Sch A regulated to modulate metabolic disorders, especially energy metabolism, and the metabolite of Sch A M5 was identified as a most likely active metabolite. Conclusion: The results suggested the feasibility of combining metabolomics and network analysis to reflect the effects of Sch A on the biological network and the metabolic state of PF and to evaluate the drug efficacy of Sch A and its related mechanisms. Graphical Abstract:


  • Open Access

    The Role and Mechanism of Hyperoside against Depression-like Behavior in Mice via the NLRP1 Inflammasome

    by Aoqi Song, Zhenghua Wu, Wenjuan Zhao, Wenqing Shi, Ru Cheng, Jingjing Jiang, Zhuojun Ni, Han Qu, Xijier Qiaolongbatu, Guorong Fan, et al.

    Background and Objectives: Hypericum perforatum (HP) is widely used for depressive therapy. Nevertheless, the antidepressant effect and potential mechanism of hyperoside (Hyp), the main active component of HP, have not been determined. Materials and Methods: We performed ultra-performance liquid chromatography–quadrupole-time-of-flight–tandem mass spectrometry (UPLC-Q-TOF-MS/MS) technology to analyze the components in HP. Using data mining and network pharmacology methods, combined with Cytoscape v3.7.1 and other software, the active components, drug-disease targets, and key pathways of HP in the treatment of depression were evaluated. Finally, the antidepressant effects of Hyp and the mechanism involved were verified in chronic-stress-induced mice. Results: We identified 12 compounds from HP. Hyp, isoquercetin, and quercetin are the main active components of HP. The Traditional Chinese Medicine Systems Pharmacology Database (TCMSP), the Analysis Platform, DrugBank, and other databases were analyzed using data mining, and the results show that the active components of HP and depression are linked to targets such as TNF-, IL-2, TLR4, and so on. A potential signaling pathway that was most relevant to the antidepressant effects of Hyp is the C-type lectin receptor signaling pathway. Furthermore, the antidepressant effects of Hyp were examined, and it is verified for the first time that Hyp significantly alleviated depressive-like behaviors in chronic-stress-induced mice, which may be mediated by inhibiting the NLRP1 inflammasome through the CXCL1/CXCR2/BDNF signaling pathway. Conclusion: Hyp is one of the main active components of HP, and Hyp has antidepressant effects through the NLRP1 inflammasome, which may be connected with the CXCL1/CXCR2/BDNF signaling pathway.